Enterome announced new financing totaling €46.3 million ($52.6 million) to progress the clinical development of its first-in-class OncoMimics platform. As part of this financing, Enterome has closed a Series E round with new investors, including SymBiosis, LLC, a microbiome-focused investment vehicle, and Takeda Pharmaceutical Company Limited. Existing Enterome investors—Seventure, Health for Life Capital, Principia, Omnes Capital, and Nestlé Health Science—also participated in the round. In addition, Enterome has made a first drawdown from a loan facility provided by the European Investment Bank (EIB) under a 2018 agreement.
Enterome has two unique platforms based on the company’s knowledge of the interaction between the gut microbiome and the immune system (the ‘microbiome-immunoinflammation axis’). OncoMimics, highly effective, off-the-shelf immunotherapies against cancers and EndoMimics, a new generation of biologics for inflammatory diseases (EM101), Type 2 diabetes, and inflammatory bowel disease.
OncoMimics are microbiome-derived peptide antigens that closely mimic antigens expressed by tumor cells; they are selected based on their ability to trigger the rapid activation of memory T-cells that respond to gut bacteria and to direct a targeted cell-killing immune response against the tumor.
Enterome will use the funds primarily to progress EO2401, the first clinical candidate derived from the OncoMimics platform, into the clinic in two cancer indications. Two Phase 1/2 clinical studies in glioblastoma and adrenal tumors are planned to start during mid-2020.
Enterome expects its second OncoMimic candidate, EO2463, a new multi-peptide cancer immunotherapy, to enter the clinic in 2021 to treat B-cell malignancies (lymphomas and leukemias).
Enterome is also pursuing the development of its proprietary, next-generation EndoMimics platform, which is designed to produce a new generation of biologics with high potency and unique tolerability. These novel peptide/protein therapeutics are being developed for unmet medical needs in metabolic and inflammatory diseases.
Enterome’s lead EndoMimic candidate, EM101, is a human hormone mimetic produced by commensal bacteria. It is currently in pre-clinical development as a potential novel therapy for inflammatory bowel disease (IBD).
Enterome will also use the proceeds to support its global partner Takeda Pharma to deliver proof-of-concept clinical data with EB8018 (sibofimloc/TAK-018), an oral FimH blocker for the treatment of Crohn’s disease. Enterome retains a significant profit share in the US.